Premature babies may soon have a more practical way to navigate one of neonatology’s most delicate decisions: when rising bilirubin levels require treatment. A new paper in the Journal of Perinatology proposes a chronologic-age format for displaying consensus-based recommendations on hyperbilirubinemia in infants born before 35 weeks’ gestation. The approach is designed to make treatment guidance easier to interpret at the bedside, where clinicians must balance the danger of bilirubin toxicity against the risks and burdens of unnecessary intervention.
Bilirubin is a yellow pigment produced when the body breaks down red blood cells. In newborns, the liver’s ability to process and eliminate bilirubin is still developing, and premature infants are particularly vulnerable because they often have immature liver function, increased red-cell turnover and medical conditions that can interfere with bilirubin clearance. When unconjugated bilirubin accumulates in the blood, it can cross the blood-brain barrier and damage sensitive neural tissue. In severe cases, this can lead to acute bilirubin encephalopathy or permanent neurological injury known as kernicterus.
The challenge is that bilirubin concentrations cannot be interpreted in isolation. The same laboratory value may carry different risks depending on an infant’s maturity, age after birth, clinical stability and exposure to additional risk factors. Babies born extremely prematurely have less developed neurological defenses and may be more susceptible to bilirubin-related injury at lower concentrations than older or more mature newborns. Clinicians therefore rely on treatment thresholds that account for gestational age and the infant’s evolving condition, rather than applying a single universal cutoff.
At the request of the American Academy of Pediatrics, consensus-based recommendations for managing hyperbilirubinemia in infants below 35 weeks’ postmenstrual age were published in 2012. These recommendations provided guidance for deciding when to begin phototherapy and when to consider an exchange transfusion, a procedure in which an infant’s blood is gradually replaced to rapidly reduce bilirubin and remove potentially harmful antibodies or abnormal red cells. Because large clinical trials are difficult to conduct in extremely premature infants, the recommendations were based on expert consensus and available evidence rather than on a single definitive treatment threshold validated for every clinical situation.
The recommendations later became widely known through Premie BiliRecs, a graphical decision-support format organized according to postmenstrual age. Postmenstrual age combines the time spent in the womb with the time since birth. For example, a baby born at 28 weeks’ gestation who is four weeks old has a postmenstrual age of 32 weeks. This measure reflects developmental maturity, but it can be cumbersome in urgent clinical settings because caregivers must calculate or look up the infant’s changing age before locating the appropriate treatment range.
Premie BiliRecs was developed for infants at least 27 weeks’ postmenstrual age and at least 48 hours old. Its graphical presentation translates the consensus recommendations into age-specific zones that can support decisions about phototherapy and escalation of care. The new paper by Robert L. Stavis and John D. Guida explores a complementary format: graphing the same type of guidance by chronologic age, meaning the number of hours or days that have passed since birth. Instead of requiring clinicians to begin with postmenstrual age, the proposed format follows the infant’s life outside the womb.
That distinction could be important because bilirubin levels change rapidly during the first days after delivery. In many newborns, concentrations rise after birth, reach a peak and then decline as liver function and feeding improve. Premature infants may follow a less predictable course, particularly when they experience sepsis, respiratory disease, bruising, hemolysis, poor feeding or instability. A chronologic-age graph could allow clinicians to track the infant’s bilirubin trajectory directly against time since birth while still incorporating the maturity-based risk categories that underpin the original recommendations.
Technically, the proposed format is not presented as a new biological threshold or as proof that chronologic age is superior to postmenstrual age. Rather, it is a method for displaying existing consensus guidance in a different coordinate system. The clinical meaning of a treatment line remains dependent on gestational maturity and the infant’s condition. The value of the reformatted graph lies in reducing calculation steps, clarifying how thresholds evolve over time and potentially lowering the risk of selecting the wrong reference curve during a rapidly changing clinical situation.
Such tools are especially relevant in neonatal intensive care units, where treatment decisions are made amid continuous changes in laboratory values, respiratory support, nutrition and medication. Phototherapy is generally effective and noninvasive, but it requires prolonged exposure under specialized lights, protection of the eyes and careful attention to temperature, hydration and feeding. Exchange transfusion is far more invasive and can cause serious complications, so the decision to proceed depends on the bilirubin level, the rate at which it is rising, the infant’s risk factors and the response to phototherapy. Clear visual guidance may help teams recognize when escalation is warranted without treating every elevated value as an emergency.
The authors’ chronologic-age approach arrives as neonatal clinicians increasingly use electronic decision-support systems and automated laboratory monitoring. A graph that aligns with the timing of bilirubin measurements could be integrated into digital charts, potentially displaying the infant’s values alongside recommended treatment zones. However, the format still requires clinical judgment. Bilirubin measurements may vary according to the testing method, and a graph cannot independently determine whether an infant has hemolysis, infection, acidosis or other conditions that increase neurological risk. The paper therefore represents a practical refinement of how recommendations are communicated, not a replacement for bedside assessment.
By reshaping a familiar set of recommendations around the clock that governs every newborn’s care, the proposed format could make hyperbilirubinemia management more intuitive for clinicians and safer for vulnerable premature infants. Its broader significance is a reminder that medical decision support depends not only on the quality of the underlying evidence, but also on how easily that evidence can be used under pressure. For babies born before 35 weeks’ gestation, where uncertainty remains unavoidable and the consequences of delayed treatment can be profound, a clearer map may be a meaningful step toward more consistent care.
Subject of Research: Management of hyperbilirubinemia in premature infants born before 35 weeks’ gestation, with a focus on chronologic-age graphical decision support.
Article Title: Hyperbilirubinemia in premature infants <35 weeks’ gestation: A chronologic age format for graphing consensus-based recommendations
Article References: Stavis, R.L., Guida, J.D. “Hyperbilirubinemia in premature infants <35 weeks’ gestation: A chronologic age format for graphing consensus-based recommendations.” Journal of Perinatology (2026). https://doi.org/10.1038/s41372-026-02855-y
Image Credits: AI Generated
DOI: 10.1038/s41372-026-02855-y
Keywords: Hyperbilirubinemia, premature infants, preterm birth, bilirubin, phototherapy, exchange transfusion, postmenstrual age, chronologic age, Premie BiliRecs, neonatal intensive care
